Product Name
CYP7B1, siRNA
Full Product Name
CYP7B1 siRNA (Human)
Product Synonym Names
25-hydroxycholesterol 7-alpha-hydroxylase; Cytochrome P450 7B1; Oxysterol 7-alpha-hydroxylase
Product Gene Name
CYP7B1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for O75881
Specificity
CYP7B1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CYP7B1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CYP7B1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CYP7B1 sirna
siRNA to inhibit CYP7B1 expression using RNA interference
Applications Tested/Suitable for CYP7B1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CYP7B1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_004811.1
[Other Products]
NCBI GenBank Nucleotide #
NM_004820.3
[Other Products]
UniProt Primary Accession #
O75881
[Other Products]
UniProt Secondary Accession #
Q9UNF5; B2RN07[Other Products]
UniProt Related Accession #
O75881[Other Products]
Molecular Weight
58,256 Da
NCBI Official Full Name
25-hydroxycholesterol 7-alpha-hydroxylase
NCBI Official Synonym Full Names
cytochrome P450, family 7, subfamily B, polypeptide 1
NCBI Official Symbol
CYP7B1??[Similar Products]
NCBI Official Synonym Symbols
CP7B; CBAS3; SPG5A
??[Similar Products]
NCBI Protein Information
25-hydroxycholesterol 7-alpha-hydroxylase
UniProt Protein Name
25-hydroxycholesterol 7-alpha-hydroxylase
UniProt Synonym Protein Names
Cytochrome P450 7B1; Oxysterol 7-alpha-hydroxylase
Protein Family
25-hydroxycholesterol 7-alpha-hydroxylase
UniProt Gene Name
CYP7B1??[Similar Products]
UniProt Entry Name
CP7B1_HUMAN
NCBI Summary for CYP7B1
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This endoplasmic reticulum membrane protein catalyzes the first reaction in the cholesterol catabolic pathway of extrahepatic tissues, which converts cholesterol to bile acids. This enzyme likely plays a minor role in total bile acid synthesis, but may also be involved in the development of atherosclerosis, neurosteroid metabolism and sex hormone synthesis. [provided by RefSeq, Jul 2008]
UniProt Comments for CYP7B1
CYP7B1: Defects in CYP7B1 are the cause of spastic paraplegia autosomal recessive type 5A (SPG5A). Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Defects in CYP7B1 are the cause of congenital bile acid synthesis defect type 3 (CBAS3). Clinical features include severe cholestasis, cirrhosis and liver synthetic failure. Hepatic microsomal oxysterol 7-alpha-hydroxylase activity is undetectable. Belongs to the cytochrome P450 family.
Protein type: Lipid Metabolism - primary bile acid biosynthesis; EC 1.14.13.100; Oxidoreductase; Endoplasmic reticulum
Chromosomal Location of Human Ortholog: 8q21.3
Cellular Component: endoplasmic reticulum membrane
Molecular Function: 25-hydroxycholesterol 7alpha-hydroxylase activity; iron ion binding; heme binding; oxysterol 7-alpha-hydroxylase activity
Biological Process: cholesterol metabolic process; bile acid biosynthetic process; bile acid metabolic process; xenobiotic metabolic process; sterol metabolic process; transmembrane transport; positive regulation of epithelial cell proliferation; negative regulation of estrogen receptor signaling pathway
Disease: Spastic Paraplegia 5a, Autosomal Recessive; Bile Acid Synthesis Defect, Congenital, 3
Research Articles on CYP7B1
1. Spastic paraplegia type 5 has a higher frequency in Taiwanese than in other ethnic groups, associated with a CYP7B1 founder mutation and its phenotype is characterized by pronounced dorsal column sensory loss, with cerebellar ataxia in some patients.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
